Palbociclib plus in hormone_receptor-positive cancer: multicenter study in the

HIGHLIGHTS

• who: Metastatic breast cancer et al. from the northwest of China have published the Article: Palbociclib plus in hormone_receptor-positive cancer: multicenter study in the, in the Journal: (JOURNAL)
• what: In this study, Palbociclib-based therapy was shown to benefit MBC patients even with later lines of therapy, indicating that Palbociclib plus ET is a viable treatment option for patients with HR+/HER2- MBC in China. To the younger median age mentioned above, the main reason is the inclusion of more premenopausal women (31% vs. 0%), and the higher percent of patients who had already . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.